Market capitalization | GBP154.55b |
Enterprise Value | GBP174.47b |
P/E (TTM) P/E ratio | 30.18 |
EV/FCF (TTM) EV/FCF | 22.27 |
EV/Sales (TTM) EV/Sales | 4.32 |
P/S ratio (TTM) P/S ratio | 3.83 |
P/B ratio (TTM) P/B ratio | 5.09 |
Dividend yield | 2.29% |
Last dividend (FY23) | GBP2.28 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
29 Analysts have issued a AstraZeneca forecast:
29 Analysts have issued a AstraZeneca forecast:
Sep '24 |
+/-
%
|
||
Revenue | 40,380 40,380 |
10%
10%
|
|
Gross Profit | 29,736 29,736 |
14%
14%
|
|
EBITDA | 12,460 12,460 |
19%
19%
|
EBIT (Operating Income) EBIT | 7,989 7,989 |
34%
34%
|
Net Profit | 5,119 5,119 |
7%
7%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Head office | United Kingdom |
CEO | Pascal Soriot |
Employees | 89,900 |
Founded | 1992 |
Website | www.astrazeneca.co.uk |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.